In its first Litmus test after an ‘ambitious’ CMD in June 2021, the British giant has put up a decent show. The group witnessed recovery in the base business, particularly in vaccines which benefited from the sales of COVID-19 vaccine adjuvant. While the near term continues be tricky due to resurfacing COVID-19 concerns, encouraging trends on the COVID-19 vaccine / treatment front and growing HIV and oncology prowess should calm the nerves.
29 Jul 2021
Underlying business recovers, full-year earnings outlook reiterated
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Underlying business recovers, full-year earnings outlook reiterated
GSK plc (GSK:LON) | 1,662 29.9 0.1% | Mkt Cap: 68,442m
- Published:
29 Jul 2021 -
Author:
Amandeep Goyal -
Pages:
5
In its first Litmus test after an ‘ambitious’ CMD in June 2021, the British giant has put up a decent show. The group witnessed recovery in the base business, particularly in vaccines which benefited from the sales of COVID-19 vaccine adjuvant. While the near term continues be tricky due to resurfacing COVID-19 concerns, encouraging trends on the COVID-19 vaccine / treatment front and growing HIV and oncology prowess should calm the nerves.